Etan Orgel, MD

Professor of Clinical Pediatrics

Image of Etan Orgel, MD
Is this your profile? Click to edit

Overview

Dr. Orgel is an attending physician in the Cancer and Blood Disease Institute at the Children’s Hospital Los Angeles (Los Angeles, CA). Dr. Orgel’s clinical specialty is in treating higher risk and rare malignant hematology. He is an international expert in treating Mixed-Phenotype Acute Leukemia (MPAL), a particularly rare form of leukemia. He possesses an academic appointment as a Professor of Clinical Pediatrics in the Keck School of Medicine of the University of Southern California (USC) and earned a Masters of Science in Clinical and Biomedical Investigations from the Department of Preventive Medicine at USC.

Dr. Orgel’s primary research interest lies in the field of cancer control (reducing acute and long-term treatment-related toxicities). Dr. Orgel leads a translational research program focused on reducing toxicities from common chemotherapies with the goal of improving both treatment delivery and quality of life for children with cancer. Dr. Orgel’s investigator-initiated research currently includes two primary areas of emphasis (1) new agents and novel strategies to reduce chemotherapy-induced hearing loss, and (2) targeting overweight and obesity in pediatric ALL to reduce chemoresistance, toxicity, and relapse.

Publications

  • Toxicity from asparaginase during acute lymphoblastic leukemia induction: a report from the Children’s Oncology Group. Blood Adv. 2026 Jul 28; 10(14):4923-4930.. View in PubMed
  • On Hierarchical Composite Endpoints in Pediatric Cancer Supportive Care: Illustrative Examples From Two Multi-Center Phase-III Randomized Clinical Trials. Pediatr Blood Cancer. 2026 Jul 25.. View in PubMed
  • Neurofilament Light Chain: A Potential Biomarker for Chemotherapy-Induced Peripheral Neuropathy in Adolescent Young Adults. J Adolesc Young Adult Oncol. 2026 Jul 01; 21565333261464963.. View in PubMed
  • Impact of Cisplatin-Induced Hearing Loss on Quality of Life in Childhood Cancer Survivors. JCO Oncol Pract. 2026 Jun 22.. View in PubMed
  • Before the Race Even Starts: Early Intervention to Prevent Long-Term Late Effects From Childhood Cancer Therapies. Am Soc Clin Oncol Educ Book. 2026 Jun; 46(3):e517242.. View in PubMed
  • Factors associated with unplanned healthcare encounters in pediatric cancer patients. Support Care Cancer. 2026 May 21; 34(6).. View in PubMed
  • Ethnic Differences in the Association Between SOD2 rs4880 and Hepatotoxicity in Pediatric Acute Lymphoblastic Leukemia: A Report From the REDIAL Consortium. Pediatr Blood Cancer. 2026 Jul; 73(7):e70387.. View in PubMed
  • Lipidomic profiles associated with treatment related hepatotoxicity in children with acute lymphoblastic leukemia. Support Care Cancer. 2026 Feb 17; 34(3):209.. View in PubMed
  • Evaluating the use of hierarchical composite endpoints in pediatric cancer supportive care clinical trials: Illustrative examples from two multi-center phase-III randomized clinical trials. medRxiv. 2026 Jan 23.. View in PubMed
  • Incidence and outcomes of treatment-associated hepatotoxicity during pediatric acute lymphoblastic leukemia induction therapy: a Reducing Ethnic Disparities in Acute Leukemia (REDIAL) Consortium report. Haematologica. 2026 Jul 01; 111(7):2435-2439.. View in PubMed